Navigation Links
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
Date:6/7/2008

reatment guidelines recommend aggressive treatment of lipids in patients with mixed dyslipidemia and type 2 diabetes," said Peter H. Jones, M.D., FACP, Methodist DeBakey Heart and Vascular Center, Houston, and a lead investigator of the trial. "A comprehensive approach may be necessary to help these patients manage their lipids."

About the Study

This 12-week, multi-center, double blind, controlled Phase III study of 1,400 patients evaluated the efficacy and safety of TriLipix in combination with rosuvastatin on multiple lipid parameters. Patients enrolled in the study had multiple lipid problems, with baseline LDL greater than or equal to 130 mg/dL, HDL less than 40 mg/dL for males and less than 50 mg/dL for females and triglycerides greater than or equal to 150 mg/dL.

Patients were randomized to receive TriLipix (135mg) combined with either 10mg or 20mg of rosuvastatin, TriLipix alone (135mg) or rosuvastatin alone (10mg, 20mg or 40mg). The 40mg rosuvastatin arm was included in the study to assess safety and adverse events, but was not included in the statistical analysis.

The primary comparisons were mean percent change in HDL and triglycerides for TriLipix combined with rosuvastatin compared to rosuvastatin alone, and mean percent change in LDL for TriLipix combined with rosuvastatin compared to TriLipix alone. The combination of TriLipix and rosuvastatin significantly improved LDL compared to TriLipix alone, and significantly improved HDL and triglycerides compared to rosuvastatin alone.

A total of 276 patients included in the primary efficacy analysis had type 2 diabetes and were included in a sub-group analysis. Diabetic patients treated with the combination of TriLipix 135mg and rosuvastatin 10mg had an increase in HDL of 21.0 percent and decrease in triglycerides of 44.7 percent compared to an HDL increase of 6.6 percent and triglyceride decrease of 28.8 percent with rosuvastatin 10mg alone. LDL decreased 37.1 percent with t
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
2. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
3. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
4. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
5. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
6. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
7. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
8. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
11. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... -- Acumed,s new SLIC Screw System - a jointed ... place and insert the screw accurately - offers surgeons ... repair or reconstruction as it holds the bones reduced ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw is ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Pharma market research thought leaders are discovering new ways ... the pharmaceutical industry. The last twelve months has shown ... market research is no exception. But those who are ... will certainly rise to be the new leaders of tomorrow. ...
... Nov. 11 VIVUS, Inc. (Nasdaq: VVUS ) today announced ... the company at the Lazard Capital Markets 6th Annual Healthcare Conference. ... in New York, NY on Wednesday, November 18, 2009 at 1:45 ... presentation will be available at http://ir.vivus.com . , ...
Cached Medicine Technology:Executives Reveal Secrets to Capitalize on New Developments in Pharmaceutical Marketing Research 2VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... are inadequate in countries with high rates of multi-drug ... MDR-TB, patients are nearly twice as likely to fail ... rates, according to a new analysis of World Health ... TB treatment regimens need to updated and revised to ...
... completion of health risk assessment resulted in a 65% employee completion rate; ... ... 1, 2008 -- Employers are increasingly using incentives as the carrot to ... brief from HealthFitness (OTC BB: HFIT) zeros in on the use of ...
... Nearly six million people in the UK have had self-inflicted DIY disasters. ... home insurance as a result. , ... Cardiff, UK (PRWEB) August 1, ... disasters, according to Confused.com - the UK,s leading insurance price comparison site., ...
... in the document scanning industry, announced that its ... http://www.imagedocusa.com . The site introduces a ... businesses to "Go Paperless!" ImageDoc USA, headquartered ... and has created a reputation as a niche ...
... World Vision calls for action to protect, care for children impacted by ... HIV and AIDS, ... ... Aug. 1 A leading humanitarian agency has,today warned that the world,s biggest conference on ...
... shows that cannabinoid cell surface receptor CB1 plays a ... the Aug. 1 edition of the journal Cancer ... and nausea, elevating mood and stimulating appetite by serving ... signaling molecules. It now may serve as a new ...
Cached Medicine News:Health News:Strategies to control TB outdated, inadequate 2Health News:HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success 2Health News:HealthFitness Guides Incentives Strategy to Spark Participation in American Electric Power's Employee Health and Wellness Initiative New Issue Brief Highlights AEP program, Outlines Elements for Success 3Health News:DIY Disasters Cost the Average Brit 669.58, Says Confused.com* 2Health News:DIY Disasters Cost the Average Brit 669.58, Says Confused.com* 3Health News:ImageDoc USA, Inc. Launches "Go Paperless!" Website 2Health News:International AIDS Conference an 'Expensive Talking Shop' Unless More Done for Children 2Health News:International AIDS Conference an 'Expensive Talking Shop' Unless More Done for Children 3Health News:Turned-off cannabinoid receptor turns on colorectal tumor growth 2Health News:Turned-off cannabinoid receptor turns on colorectal tumor growth 3
... three preferred cardiac markers are ... immunoassay system. Cardiac Troponin I ... very high sensitivity and specificity ... appears very soon following AMI. ...
IRMA kit for detection of the cardiac marker Myoglobin...
... For the quantitative determination of myoglobin ... Myoglobin ELISA test is based on the ... assay. The assay system utilizes a unique ... determinant on the myoglobin molecule. Mouse monoclonal ...
... Prolactin ELISA kit is used for the ... or plasma. Human prolactin (lactogenic hormone) is ... molecular weight of approximately 23,000 daltons. The ... phase direct sandwich ELISA method. The samples ...
Medicine Products: